Type 2 Diabetes Focus# Recommendation : Tirzepatide Reason : Tirzepatide has 5 SURPASS T2D trials, FDA approval for diabetes (Mounjaro), and demonstrated superiority over semaglutide in SURPASS-2
Cellular changes in the postmortem hippocampus in major depression
GLP1R agonists increase heart rate and might not be beneficial in individuals with severe left ventricular dysfunction, reduced ejection fraction and/or a history of repeated hospitalization for heart failure
Real-world data link semaglutide, tirzepatide to improved heart failure outcomes Semaglutide and tirzepatide can help patients with heart failure with preserved ejection fraction (HFpEF) significantly improve their heart health, according to new data presented at ESC Congress 2025, the annual meeting of the European Society of Cardiology
Patients were also excluded if they had a history of excessive alcohol use, abuse, or use disorder